3 days popular7 days popular1 month popular3 months popular

Hormone Combination Shows Promise In The Treatment Of Obesity And Diabetes

A new treatment combining two hormones can reduce appetite, according to new research presented at the Society for Endocrinology annual conference in Harrogate, UK. This early study from an internationally-renowned team at provides ‘first in man’ evidence that a combined therapy using the hormones glucagon and glucagon-like peptide 1 (GLP-1) may form the basis for a new treatment for obesity and diabetes in the future.

Previous results from in animal studies showed that glucagon/GLP-1 combination might be an effective lead to combat obesity and diabetes. The hormones play key roles in regulating . Glucagon works in opposition to insulin, preventing the storage of glucose in fat deposits and the liver, and raising levels. GLP-1 stimulates the release of insulin to lower and also acts at the brain to reduce appetite.

The research team, led by , set out to identify whether glucagon and GLP-1 given in combination might work together to reduce appetite. In this small study, 16 human volunteers were randomly allocated to a sequence of four treatment infusions for 120 minutes, separated by at least three days, each: 1) glucagon, 2) GLP-1, 3) glucagon and GLP-1 in combination and 4) a saline infusion as a control. Double-blind crossover experiments such as these are used across clinical research to reliably identify cause and effect in a series of interventions.

The team provided the subjects with a meal at 90 minutes into each infusion, measured the amount of oxygen consumed, took blood samples to measure blood sugar and metabolic hormone levels, and took readings for pulse, blood pressure and nausea, all both at baseline and during the infusions. This provided data on energy intake (amount of food consumed), energy expenditure (oxygen used), blood sugar control, and the safety of and tolerance to the treatment.

The energy intake during the meal was 1086+/-110.1kcal for the control group vs. 879+/-94.2kcal for the hormone combination group: a significant reduction of 13% (p<0.05) which was also not seen when either hormone was given alone (glucagon: 1086+/-96.9kcal, GLP-1: 1052+/-81.3kcal; p>0.05). A non-significant trend toward increased energy expenditure was also observed in the combination and glucagon-alone groups. The infusions were tolerated safely.

The data show that the promising findings using a glucagon/GLP-1 combination in mice can be replicated in man. Appetite was significantly reduced during the compared to the glucagon, GLP-1 alone or saline infusions. The group must now test this glucagon/GLP-1 in more people and for longer periods of time to see if the effects can be sustained in the long term.

Professor Stephen Bloom, Head of Division of Diabetes, Endocrinology and Metabolism at Imperial College London said:

“The hormones glucagon and GLP-1 are both used by the body to control blood sugar and metabolism, so there is great interest in utilising them to find new treatments for obesity and type 2 diabetes. “We found that volunteers treated with a glucagon/GLP-1 combination consumed significantly less food. These data replicate our findings in animals, suggesting that a glucagon/GLP-1 combination may be a promising lead from which to develop a new treatment for obesity and diabetes.

“13% is a big reduction in food intake by anyone’s standards, but our experiment is only an appetiser. An effective future treatment will need to suppress appetite in the long term, so we next aim to establish whether the effects can be sustained to lead to real weight loss.” The Society for Endocrinology BES 2013 conference is Britain’s biggest scientific meeting on hormones, and is taking place at the Harrogate International Centre from 18-21 March 2013. For the full programme, please click here.


“Energy intake following infusion of glucagon and GLP-1: a double-blind crossover study”,
Jaimini Cegla et al.
The Society for Endocrinology BES 2013 conference